Emergency Department Substance Use Surveillance System

The summary for the Emergency Department Substance Use Surveillance System grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Office of National Drug Control Policy, which is the U.S. government agency offering this grant.

Emergency Department Substance Use Surveillance System: The Office of National Drug Control Policy (ONDCP) is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine and geographically expand a methodology for obtaining drug early warning indicators through broader testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations – including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. A similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including fentanyl and methamphetamine, to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. Bypassing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. Supplemental validation of testing gaps, needs, and positivity trends against other data sources, such as de-identified electronic health records from patients treated in the hospital care setting is also desired. ONDCP is seeking to apply this testing methodology and insight from supplemental analyses to Emergency Department populations in locations throughout the United States to reinforce best practice guidelines, testing standardization, and build local and national surveillance capacity.